Report on International Healthcare Systems Notes High Costs in United States and Equity Challenges
The Commonwealth Fund has published a report that provides a comprehensive look into healthcare systems around the world. In the [...]
ISPOR Publishes Good Practices Report
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) task force has published its Good Practices Report. The purpose of [...]
ICER Will Consider AstraZeneca Asthma Treatment
The Institute for Clinical and Economic Review (ICER) is set to evaluate AstraZeneca’s tezepelumab. ICER will consider the efficacy and [...]
ISPOR Signal Virtual Event on Value and Pricing Strategies
ISPOR will host its second event in its new Signal series on June 25th, from 11:00 AM to 12:00 PM [...]
Can Improved QALYs Effectively Reduce Drug Prices?
Dan Ollendorf of Tuft’s Center for the Evaluation of Value and Risk in Health (CEVR) shared his thoughts on how [...]
Non-Legislative and Legislative Actions Could Reduce High Prescription Drug Prices
Reducing prescription drug prices in the United States continues to be a point of contention. Although legislative measures are expected [...]
ICER Publishes Draft Evidence Report on Alzheimer’s Disease Drug
The Institute for Clinical and Economic Review (ICER) published a Draft Evidence Report regarding Biogen’s aducanumab. The drug is designed to treat [...]
Model N and Global Pricing Innovations Partner to Improve Market Access
Model N and Global Pricing Innovations have announced a new partnership designed to improve market access. The companies are leaders [...]
JAMA Report on Reducing Prescription Drug Prices Using Legislation, Notes 159% List Price Increase in 11 Years
A new report discusses legislation that could reduce skyrocketing drug prices. Attempts at the state level have put forth unsupported [...]
New Report Claims Reducing Drug Prices Will Not Impact Innovation, Discusses HTA Solution
Patients for Affordable Drugs released a report on how lowering drug prices would fail to impact innovation. The authors note [...]
ICER’s Protocol on Unsupported Price Increases Discusses 250 Drugs
The Institute for Clinical and Economic Review (ICER) recently published a protocol detailing how it determines unjustified price increases. The [...]
Upcoming Virtual Discussion on Reducing High Prescription Drug Prices Without Impacting Innovation
Patients for Affordable Drugs will host a virtual session on overcoming high drug prices on May 18th at 7 PM [...]
New Study Analyzes List and Net Prices of Diabetes Drugs
A new study considers the prices of three categories of drugs used in diabetes. The authors note an increase in [...]
New JMCP Article Discusses Calculating the Price Tag of Gene Therapies
An article published in the Journal of Managed Care & Specialty Pharmacy (JMCP) focuses on the price considerations of new [...]
Insights on Excessive Drug Costs and Using QALYs to Determine Value
Dan Ollendorf of the Center for the Evaluation of Value and Risk in Health at Tufts University Medical Center and [...]
ICER’s New Whitepaper Features Insight on FDA’s Accelerated Approval Pathway and Proposes Drug Pricing Reform
The Institute for Clinical and Economic Review (ICER) published a whitepaper discussing the Food and Drug Administration’s Accelerated Approval Pathway (AAP). The [...]
New Podcast Featuring ICER President on Consequences of High Drug Prices and Thoughts on New Cholesterol-Reducing Drugs
A recent Managed Healthcare Executive podcast featured ICER President and Founder Dr. Steven Pearson. ICER recently published a report on [...]
Federal Agency Proposes Penalties if Pharma Forgoes Clinical Trials
The Medicaid and CHIP Payment and Access Commission has voted to demand pharma companies pay higher Medicaid rebates if they [...]
Will Biden Budget Tackle Drug Pricing?
The Biden administration has announced its skinny budget. One major omission was any mention of drug pricing regulation. However, the [...]
West Virginia Takes Legislative Action to Lower Drug Costs, Improve Health Equity
West Virginia passed a law that will compel payers and PBMs (Pharmacy Benefit Managers) to pass on medication savings to [...]
Maine Citizens Demand Prescription Drug Pricing Action in Public Hearing; 219,000 Mainers Can’t Afford Medication
Maine recently held a public meeting where Mainers discussed how skyrocketing drug prices lead to extreme financial hardship, pain, and [...]
Use of Reference Pricing in United States Could Lead to Global Consequences
According to a national poll, Americans think that reducing drug prices is one of the top priorities at the federal [...]
HTA Whitepaper Discusses Resulting Value and Economic Benefits
In a whitepaper by researchers at the USC Schaeffer Center and Aspen Institute Advisory Panel, the authors discuss how an [...]
How Will States Tackle Unsupported Price Increases?
ICER’s report on UPIs (Unsupported Price Increases) has led lawmakers to consider legislative measures to restrict the prices of prescription [...]
New Book on Pharma Market Access Now Available
A new book by Kasem Akhras, PharmD, is now available on Amazon, both as a physical book and as an [...]